1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Chronic Diseases
4.2.2 Rise in Geriatric Population
4.3 Market Restraints
4.3.1 Side Effects of Heparin
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Unfractionated Heparin
5.1.2 Low Molecular Weight Heparin (LMWH)
5.1.3 Ultra-Low Molecular Weight Heparin (ULMWH)
5.2 By Source
5.2.1 Bovine
5.2.2 Porcine
5.3 By Application
5.3.1 Atrial Fibrillation & Heart Attack
5.3.2 Stroke
5.3.3 Deep Vein Thrombosis (DVT)
5.3.4 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Aspen Pharmacare Holdings Limited
6.1.2 B Braun Melsungen AG
6.1.3 Baxter International Inc.
6.1.4 Bioiberica
6.1.5 Dr. Reddy's Laboratories
6.1.6 Hebei Changshan Biochemical Pharmaceutical
6.1.7 Leo Pharma A/S
6.1.8 Opocrin S.p.A
6.1.9 Pfizer Inc.
6.1.10 LABORATORIOS FARMACEUTICOS ROVI SA

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Companies Mentioned
 - Aspen Pharmacare Holdings Limited
- B Braun Melsungen AG
- Baxter International Inc.
- Bioiberica
- Dr. Reddy's Laboratories
- Hebei Changshan Biochemical Pharmaceutical
- Leo Pharma A/S
- Opocrin S.p.A
- Pfizer Inc.
- LABORATORIOS FARMACEUTICOS ROVI SA